Free Trial

Cullinan Therapeutics (CGEM) Competitors

Cullinan Therapeutics logo
$7.54 -0.29 (-3.70%)
As of 02:02 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

CGEM vs. LENZ, SNDX, SION, XERS, TSHA, ZYME, NUVB, ARDX, AMPH, and TRML

Should you be buying Cullinan Therapeutics stock or one of its competitors? The main competitors of Cullinan Therapeutics include LENZ Therapeutics (LENZ), Syndax Pharmaceuticals (SNDX), Sionna Therapeutics (SION), Xeris Biopharma (XERS), Taysha Gene Therapies (TSHA), Zymeworks (ZYME), Nuvation Bio (NUVB), Ardelyx (ARDX), Amphastar Pharmaceuticals (AMPH), and Tourmaline Bio (TRML). These companies are all part of the "pharmaceutical products" industry.

Cullinan Therapeutics vs. Its Competitors

Cullinan Therapeutics (NASDAQ:CGEM) and LENZ Therapeutics (NASDAQ:LENZ) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, valuation, profitability, risk, institutional ownership, analyst recommendations, earnings and dividends.

LENZ Therapeutics' return on equity of -25.63% beat Cullinan Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Cullinan TherapeuticsN/A -36.56% -34.82%
LENZ Therapeutics N/A -25.63%-24.43%

In the previous week, Cullinan Therapeutics had 5 more articles in the media than LENZ Therapeutics. MarketBeat recorded 12 mentions for Cullinan Therapeutics and 7 mentions for LENZ Therapeutics. Cullinan Therapeutics' average media sentiment score of 1.49 beat LENZ Therapeutics' score of 0.38 indicating that Cullinan Therapeutics is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Cullinan Therapeutics
4 Very Positive mention(s)
3 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
LENZ Therapeutics
1 Very Positive mention(s)
1 Positive mention(s)
2 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral

LENZ Therapeutics is trading at a lower price-to-earnings ratio than Cullinan Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Cullinan TherapeuticsN/AN/A-$167.38M-$3.23-2.33
LENZ TherapeuticsN/AN/A-$49.77M-$1.90-21.04

Cullinan Therapeutics currently has a consensus price target of $26.00, suggesting a potential upside of 244.83%. LENZ Therapeutics has a consensus price target of $52.80, suggesting a potential upside of 32.10%. Given Cullinan Therapeutics' higher probable upside, analysts clearly believe Cullinan Therapeutics is more favorable than LENZ Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Cullinan Therapeutics
1 Sell rating(s)
1 Hold rating(s)
5 Buy rating(s)
0 Strong Buy rating(s)
2.57
LENZ Therapeutics
1 Sell rating(s)
0 Hold rating(s)
5 Buy rating(s)
0 Strong Buy rating(s)
2.67

Cullinan Therapeutics has a beta of -0.12, indicating that its stock price is 112% less volatile than the S&P 500. Comparatively, LENZ Therapeutics has a beta of 0.5, indicating that its stock price is 50% less volatile than the S&P 500.

86.3% of Cullinan Therapeutics shares are owned by institutional investors. Comparatively, 54.3% of LENZ Therapeutics shares are owned by institutional investors. 6.1% of Cullinan Therapeutics shares are owned by insiders. Comparatively, 6.9% of LENZ Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Summary

LENZ Therapeutics beats Cullinan Therapeutics on 7 of the 12 factors compared between the two stocks.

Get Cullinan Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for CGEM and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CGEM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

CGEM vs. The Competition

MetricCullinan TherapeuticsMED IndustryMedical SectorNASDAQ Exchange
Market Cap$448.46M$3.37B$6.06B$10.50B
Dividend YieldN/A2.31%5.73%4.82%
P/E Ratio-2.3522.0585.4527.28
Price / SalesN/A476.49593.90134.93
Price / CashN/A44.9825.7730.18
Price / Book0.7410.4712.696.76
Net Income-$167.38M-$52.47M$3.32B$276.46M
7 Day Performance28.01%1.09%0.54%0.87%
1 Month Performance15.47%14.86%9.47%8.20%
1 Year Performance-53.54%21.37%79.06%43.74%

Cullinan Therapeutics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
CGEM
Cullinan Therapeutics
3.3021 of 5 stars
$7.54
-3.7%
$26.00
+244.8%
-51.7%$448.46MN/A-2.3530Positive News
LENZ
LENZ Therapeutics
1.7408 of 5 stars
$46.11
-5.4%
$49.60
+7.6%
+56.3%$1.39BN/A-24.27110
SNDX
Syndax Pharmaceuticals
3.6175 of 5 stars
$16.40
+5.1%
$39.22
+139.2%
-20.5%$1.34B$23.68M-4.22110
SION
Sionna Therapeutics
2.693 of 5 stars
$29.25
-2.5%
$38.00
+29.9%
N/A$1.32BN/A0.0035
XERS
Xeris Biopharma
2.7511 of 5 stars
$8.13
-0.9%
$7.08
-12.9%
+173.2%$1.32B$203.07M-38.71290
TSHA
Taysha Gene Therapies
2.3753 of 5 stars
$4.42
-7.1%
$9.00
+103.6%
+151.2%$1.30B$8.33M-13.00180
ZYME
Zymeworks
0.0698 of 5 stars
$16.68
-1.5%
N/AN/A$1.27B$122.87M-17.20460Analyst Upgrade
Gap Up
NUVB
Nuvation Bio
2.7867 of 5 stars
$3.77
+1.6%
$7.86
+108.4%
+62.3%$1.27B$7.87M-5.9860Analyst Forecast
ARDX
Ardelyx
4.3319 of 5 stars
$5.20
-1.1%
$11.70
+125.0%
-17.1%$1.27B$333.61M-22.6190News Coverage
AMPH
Amphastar Pharmaceuticals
4.4998 of 5 stars
$26.58
-0.6%
$31.60
+18.9%
-50.6%$1.24B$722.68M9.962,028
TRML
Tourmaline Bio
1.3294 of 5 stars
$47.87
-0.1%
$45.65
-4.6%
+90.5%$1.23BN/A-13.9644

Related Companies and Tools


This page (NASDAQ:CGEM) was last updated on 10/14/2025 by MarketBeat.com Staff
From Our Partners